Literature DB >> 22235217

Hepatitis C and hepatitis B virus infection: epidemiology and risk factors in a large cohort of pregnant women in Lorestan, West of Iran.

Seyed Reza Mohebbi1, Azar Sanati, Kourosh Cheraghipour, Mohammad Rostami Nejad, Hamid Mohaghegh Shalmani, Mohammad Reza Zali.   

Abstract

BACKGROUND: There are little data on the prevalence of serological markers of hepatitis B and hepatitis C viruses in pregnant women in Iran.
OBJECTIVES: This study was designed to determine the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among pregnant women in Lorestan, west of Iran. PATIENTS AND METHODS: Serum samples of 827 pregnant women who lived in rural (36.8%) and urban areas (63.2%) of Lorestan were collected during 2007-2008. Data were obtained through questionnaires. Samples were first screened for anti-HCV and anti-HBc by ELISA. Those who were positive for anti-HBc were tested for HBsAg.
RESULTS: Anti-HBc was found in 28 of 827 pregnant women (overall prevalence, 3.4%; 14 of 523 in urban areas, 2.7%; 14 of 304 in rural areas, 4.6%). Of the 28 positive samples, 6(0.7%) were positive for HBs-Ag. Only 2 samples (0.2%) were anti-HCV-positive.
CONCLUSIONS: These results underscore the need for prenatal screening for HBV infection in pregnant women and treatment of newborns from HBsAg-positive mothers.More studies are needed to identify risk factors of HCV infection and highlight the importance of HCV screening and treatment programs.

Entities:  

Keywords:  Anti-HBc antibody; Anti-HCV antibody; HBs-Ag; Hepatitis B; Hepatitis C; Pregnant women

Year:  2011        PMID: 22235217      PMCID: PMC3234534          DOI: 10.5812/kowsar.1735143X.749

Source DB:  PubMed          Journal:  Hepat Mon        ISSN: 1735-143X            Impact factor:   0.660


1. Background

Hepatitis B virus infection (HBV) and hepatitis C virus infection (HCV) are serious public health problems worldwide; an estimated 170 and 400 million persons suffer from these infections [1][2]. HBV and HCV are a contagious diseases in Iran that can be transmitted vertically from mothers to their neonates or horizontally by blood products and body secretions [3][4]. According to the latest data in Iran, 1.2% to 9.7% of the general population has acquired hepatitis B surface antigen (HBs Ag) (about 1.5-2.5 million people), and 0.12% to 0.89% has anti-hepatitis C virus, which corresponds to about 0.5 million chronic carriers of hepatitis C [3][5][6][7]. Chronic HBV infection at birth occurs in approximately 90% of infants who are born to HBsAg- and HBeAg-positive mothers [8]. Even if they are not infected during pregnancy, children of HBV-infected mothers have a high risk of acquiring HBV infection by horizontal transmission during the first years of life [9]. On the other hand, the range of transmission of HCV from mother to child during pregnancy is between 0% and 15% [10]. The prevalence of HBV among pregnant women worldwide is approximately 5% [11], ranging from 0.6% in low-endemic regions to > 20% in high-endemic areas in the Far East and Africa [11]. In contrast, the prevalence of HCV among pregnant women worldwide is between 1% and 8% [12].

2. Objectives

There are little data on the prevalence of serological markers of HBV and HCV among pregnant women in Iran. Thus, the aim of the present study was to determine the prevalence of HBV and HCV infection among pregnant women who attended the reproduction section of rural and urban health care centers in Lorestan province, west of Iran, to identify target groups for postpartum immunization.

3. Patients and Methods

3.1. Population

In this cross-sectional study, we recruited all pregnant women who attended the reproduction section of rural and urban health care centers in Lorestan province, west of Iran, between 2007 and 2008. Those who did not wish to participate in this project were excluded from study. Of 827 pregnant women, 304 (36.8%) and 523 (63.2%) samples were collected from rural and urban areas, respectively. The subjects had a history of spontaneous deliveries, miscarriages, and previous successful pregnancies. The purpose and procedures of the study were explained to all participants by a trained researcher, and written informed consent was obtained from all subjects. Participant information, including sociodemographic information, clinical manifestation, behavioral data, age, job, prison history, tattooing, and IV drug abuse, were gathered. The study was approved by the Institutional Ethics Committee of the Research Center for Gastroenterology and Liver Disease (RCGLD), Shahid Beheshti University of Medical Sciences.

3.2. Blood Sample

To obtain serum, blood samples were taken and centrifuged to separate the serum. Serum samples were transferred to RCGLD under cold conditions by airplane and stored at -20°C. Samples were first screened for anti-HBc and anti-HCV using commercially available ELISA kits (DIA PRO Diagnostic Bioprobes, Srl., Italy). Those who were positive for anti-HBc were tested for HBsAg (ELISA kits DIA PRO Diagnostic Bioprobes, Srl., Italy).

3.3. Statistical Analysis

SPSS, version 15.0, was used for descriptive statistics. We also used corrected χ² test or Fisher’s exact test to compare percentages, and P < 0.05 was considered statistically significant.

4. Results

Eight hundred twenty seven pregnant women with mean age of 26.1 ± 5.4 (mean ± SD) years (range: 13-42 years) and mean gestational period of 5.5 ± 2.3 months, were studied. Anti-HBc was found in 28 of the 827 women. There was no difference between mean age of anti-HBc-positive patients and -negative subjects (Table).
Table

Demographic Feature of Study Population

No, (n = 827)Anti-HBc positive, No. (%), (n = 28)P valueHBs Ag positive, No. (%), (n = 6)P valueAnti-HCV positive, No. (%), (n = 2)P value
Age,y0.810.890.56
≤ 201274 (3.1)1(0.8%)1 (0.8%)
21-3052620 (3.8)3(0.6%)1(0.2%)
≥311744 (2.3)2(1.1%)0 (0%)
Location0.140.860.53
Urban52314 (2.7)4(0.8%)2 (0.4%)
Rural30414 (4.6)2(0.7%)0 (0%)
Educational level0.870.570.63
Illiterate411(2.4)1(2.4%)0 (0%)
Under Diploma3088(2.6)3 (1%)0 (0%)
Diploma35714(3.9)1(0.3%)2 (0.6%)
University Degree1215(4.1)1(0.8%)0 (0%)
Occupation0.620.630.78
Housekeeper79628(3.5)6(0.8%)2 (0.3%)
Employee310(0)0 (0%)0 (0%)
History of miscarriage0.690.490.83
Yes1306(4.6)2(1.5%)0 (0)
No69722(3.2)4(0.6%)2 (0.3%)
Of 28 anti-HBc-positive patients, 6 (0.7%) were positive for HBs-Ag; this difference was not significant between urban and rural populations. Of 827 pregnant women, 2 samples (0.2%) were anti HCV-positive. These patients were also HBs-Ag-positive and from urban areas, and none had a history of miscarriage (Table). No anti-HBc-, HBs-Ag-, or anti-HCV-positive subject had a history of tattooing or being in prison or was an IV drug user. There were no significant differences in age, history of miscarriage, occupation, education level, income, or other general socioeconomic parameters between HBs-Ag positive and negative as well as anti-HCV positive and negative (P > 0.05).

5. Discussion

Chronic liver diseases are an important health challenge worldwide, wherein HBV or HCV infection is the main cause of liver insufficiency with different verities in all over the world [13]. The seroprevalence of HBsAg in our study (0.7%) was lower than the rate of HBsAg positivity in pregnant women in different parts of Iran, including Zahedan (6.5%) [14], Qazvin (3.4%) [15], Bonab (3.2%) [16], Kerman (2.3%) [17], Ahwaz (1.7%) [18], Rafsanjan (1.3%) [19], and Yazd (0.84%) [20], but was higher than in Kashan (0.35%) [21]. Our rates are also lower than those for North Africa and Middle Eastern countries, in which the prevalence of HBsAg among pregnant women is 1.4% to 20% [14]. HBsAg positivity among pregnant women in urban areas in the US is 0.1% in Hispanics to 1% in non-Hispanic blacks; notably, HBsAg positivity is more prevalent among Asians (5.8%) [22]. Our study shows that the seroprevalence of anti-HCV is 0.2%, which is lower than a survey by Motlagh ME et al. in Ahvaz (6.25%) [23], while our study result was compatible with those of Brazilian (0.2%) and Canadian studies (0.5%) [24][25]. The limitations of our study are that we did not investigate a similar population of nonpregnant women to compare the findings and surveyed a single city in this province. In conclusion, HBV and HCV are not prevalent among pregnant women in Lorestan province compared with the rest of the country. However, this low prevalence justifies the establishment of a national program for regular screening of all pregnant women. Because most pregnant women are asymptomatic and clinically disease-free, they might not be aware that they are infected and can transmit their infection to newborns.
  11 in total

Review 1.  Breastfeeding and chronic HBV infection: clinical and social implications.

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

2.  Maternal and neonatal seroprevalence of Hepatitis B surface antigen (HBsAg) in Tripoli, Libya.

Authors:  Hamida El-Magrahe; Abdul Rahaman Furarah; Kheiria El-Figih; Sued El-Urshfany; Khalifa Sifaw Ghenghesh
Journal:  J Infect Dev Ctries       Date:  2010-03-29       Impact factor: 0.968

3.  Prevalence of hepatitis C virus (HCV) infection and its vertical transmission in Egyptian pregnant women and their newborns.

Authors:  A S Kassem; A A el-Nawawy; M N Massoud; S Y el-Nazar; E M Sobhi
Journal:  J Trop Pediatr       Date:  2000-08       Impact factor: 1.165

4.  [Hepatitis C and pregnancy: an analysis of factors associated with vertical transmission].

Authors:  Renata Vidal Cardoso Gardenal; Ernesto Antonio Figueiró-Filho; Juliana Libman Luft; Gregori Lucas Steimback Alves de Paula; Fábio Galvão Vidal; Plínio Turine Neto; Renê Augusto Almeida de Souza
Journal:  Rev Soc Bras Med Trop       Date:  2011 Jan-Feb       Impact factor: 1.581

5.  The effectiveness of screening for hepatitis C in pregnancy.

Authors:  Colleen D McDermott; Catherine C Moravac; Mark H Yudin
Journal:  J Obstet Gynaecol Can       Date:  2010-11

Review 6.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Pregnancy and chronic hepatitis B virus infection.

Authors:  Swati Sinha; Manoj Kumar
Journal:  Hepatol Res       Date:  2010-01       Impact factor: 4.288

Review 8.  Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment?

Authors:  M Arshad; S S El-Kamary; R Jhaveri
Journal:  J Viral Hepat       Date:  2011-01-07       Impact factor: 3.728

Review 9.  Epidemiology and natural history of hepatitis B.

Authors:  Brian J McMahon
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

10.  Surveillance for hepatitis B virus infection in pregnant women in Greece shows high rates of chronic infection among immigrants and low vaccination-induced protection rates: preliminary results of a single center study.

Authors:  I S Elefsiniotis; I Glynou; I Zorou; I Magaziotou; H Brokalaki; E Apostolopoulou; E Vezali; H Kada; G Saroglou
Journal:  Euro Surveill       Date:  2009-03-05
View more
  19 in total

Review 1.  Epidemiology of hepatitis C virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Seroprevalence and risk factors of Hepatitis B and Hepatitis C infections among pregnant women in the Asante Akim North Municipality of the Ashanti region, Ghana; a cross sectional study.

Authors:  Richard Ephraim; Isaac Donko; Samuel A Sakyi; Joyce Ampong; Hope Agbodjakey
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

3.  Hepatitis B surface antigen prevalence in pregnant women: A cross-sectional survey in Iran.

Authors:  Alireza Shoghli; Seyed Mahmood Nabavi; Seyed Moayed Alavian; Goodarz Kolifarhood; Mohammad Mehdi Goya; Roshanak Namazi; Mojtaba Fallahnezhad; Mansor Mohajeri; Nouraldin Mousavinasab; Rahim Sorouri Zanjani; Mohammad Reza Saeini; Ahmad Jalilvand
Journal:  Int J Prev Med       Date:  2014-12

4.  Hepatitis B surface antigen prevalence among 12,393 rural women of childbearing age in Hainan Province, China: a cross-sectional study.

Authors:  Yu Zhang; Weiming Fang; Lichun Fan; Xiaohui Gao; Yan Guo; Wenming Huang; Yukai Du
Journal:  Virol J       Date:  2013-01-18       Impact factor: 4.099

5.  Lower intrafamilial transmission rate of hepatitis B in patients with hepatitis d coinfection: a data-mining approach.

Authors:  Omid Pournik; Seyed Moayed Alavian; Leila Ghalichi; Bashir Hajibeigi; Amir Reza Razavi; Saeid Eslami
Journal:  Hepat Mon       Date:  2013-05-23       Impact factor: 0.660

6.  Lack of Association Between Transforming Growth Factor Beta 1 -509C/T and +915G/C Polymorphisms and Chronic Hepatitis B in Iranian Patients.

Authors:  Armin Hosseini Razavi; Pedram Azimzadeh; Seyed Reza Mohebbi; Seyed Masoud Hosseini; Sara Romani; Mahsa Khanyaghma; Yasin Hatami; Afsaneh Sharifian; Mohammad Reza Zali
Journal:  Hepat Mon       Date:  2014-04-07       Impact factor: 0.660

Review 7.  Interleukin 18 gene promoter polymorphisms and susceptibility to chronic hepatitis B infection: a review study.

Authors:  Mahsa Motavaf; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-07-01       Impact factor: 0.660

8.  Evaluation of antibody frequency against HBV, HCV and HTLV-1.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Seyed Reza Fatemi; Pedram Azimzadeh; Dariush Mirsattari; Azar Sanati; Afsaneh Sharifian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2012

9.  Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in iran.

Authors:  Hiva Saffar; Abolghasem Ajami; Mohammed Jafar Saffar; Jalil Shojaei; Maryam Sotudeh-Anvari; Kiarash Shams-Esfandabad; Ali Reza Khalilian
Journal:  Hepat Mon       Date:  2014-05-01       Impact factor: 0.660

10.  Hepatitis B surface antigen and associated factors among mothers who had antenatal care contact in Attat Hospital, southern Ethiopia.

Authors:  Yohannes Fikadu Geda; Hailu Desse; Molalegn Mesele Gesesse; Tamirat Melis Berhe
Journal:  SAGE Open Med       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.